BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 21304238)

  • 1. Effect of proton-pump inhibitor therapy on serum chromogranin a level.
    Pregun I; Herszényi L; Juhász M; Miheller P; Hritz I; Patócs A; Rácz K; Tulassay Z
    Digestion; 2011; 84(1):22-8. PubMed ID: 21304238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans.
    Raines D; Chester M; Diebold AE; Mamikunian P; Anthony CT; Mamikunian G; Woltering EA
    Pancreas; 2012 May; 41(4):508-11. PubMed ID: 22460728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition.
    Fossmark R; Jianu CS; Martinsen TC; Qvigstad G; Syversen U; Waldum HL
    Scand J Gastroenterol; 2008 Jan; 43(1):20-4. PubMed ID: 18938772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study.
    Sanduleanu S; Stridsberg M; Jonkers D; Hameeteman W; Biemond I; Lundqvist G; Lamers C; Stockbrügger RW
    Aliment Pharmacol Ther; 1999 Feb; 13(2):145-53. PubMed ID: 10102943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: results of a 5-year follow-up in the LOTUS trial.
    Fiocca R; Mastracci L; Attwood SE; Ell C; Galmiche JP; Hatlebakk J; Bärthel A; Långström G; Lind T; Lundell L;
    Aliment Pharmacol Ther; 2012 Nov; 36(10):959-71. PubMed ID: 22998687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy.
    Sanduleanu S; De Bruïne A; Stridsberg M; Jonkers D; Biemond I; Hameeteman W; Lundqvist G; Stockbrügger RW
    Eur J Clin Invest; 2001 Sep; 31(9):802-11. PubMed ID: 11589723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of prolonged treatment with proton pump inhibitors on serum gastrin levels and the fundus mucosa. Preliminary results].
    Cadiot G; Vissuzaine C; Pospai D; Ruszniewski P; Potet F; Mignon M
    Gastroenterol Clin Biol; 1995 Oct; 19(10):811-7. PubMed ID: 8566561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor.
    Jianu CS; Lange OJ; Viset T; Qvigstad G; Martinsen TC; Fougner R; Kleveland PM; Fossmark R; Hauso Ø; Waldum HL
    Scand J Gastroenterol; 2012 Jan; 47(1):64-7. PubMed ID: 22087794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of short-term proton pump inhibitor treatment and its discontinuation on chromogranin A in healthy subjects.
    Mosli HH; Dennis A; Kocha W; Asher LJ; Van Uum SH
    J Clin Endocrinol Metab; 2012 Sep; 97(9):E1731-5. PubMed ID: 22723311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial.
    Björnsson E; Abrahamsson H; Simrén M; Mattsson N; Jensen C; Agerforz P; Kilander A
    Aliment Pharmacol Ther; 2006 Sep; 24(6):945-54. PubMed ID: 16948806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term high-dose proton pump inhibitor administration to Helicobacter pylori-infected Mongolian gerbils enhances neuroendocrine tumor development in the glandular stomach.
    Tsukamoto H; Mizoshita T; Sasaki M; Mizushima T; Tanida S; Ozeki K; Hirata Y; Shimura T; Kataoka H; Kamiya T; Nojiri S; Tsukamoto T; Tatematsu M; Joh T
    Asian Pac J Cancer Prev; 2011; 12(4):1049-54. PubMed ID: 21790250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term gastroesophageal reflux disease therapy improves reflux symptoms in elderly patients: five-year prospective study in community medicine.
    Miyamoto M; Haruma K; Kuwabara M; Nagano M; Okamoto T; Tanaka M
    J Gastroenterol Hepatol; 2007 May; 22(5):639-44. PubMed ID: 17444849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A study on the relationship of Helicobacter pylori, gastrin and gastroesophageal reflux disease].
    Feng GJ; Hu FL; Wang HH; Liu JX
    Zhonghua Yi Xue Za Zhi; 2003 Jan; 83(2):96-9. PubMed ID: 12812673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Influence of long-term gastric acid suppression therapy on the expression of serum gastrin, chromogranin A, and ghrelin].
    Kim BW; Lee BI; Kim HK; Cho YS; Chae HS; Lee HK; Kim HJ; Han SW
    Korean J Gastroenterol; 2009 Feb; 53(2):84-9. PubMed ID: 19237833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A meal test improves the specificity of chromogranin A as a marker of neuroendocrine neoplasia.
    Jianu CS; Fossmark R; Syversen U; Hauso Ø; Waldum HL
    Tumour Biol; 2010 Oct; 31(5):373-80. PubMed ID: 20480408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and pathophysiological consequences of on-demand treatment with PPI in endoscopy-negative reflux disease. Is rebound hypersecretion of acid a problem?
    Juul-Hansen P; Rydning A
    Scand J Gastroenterol; 2011 Apr; 46(4):398-405. PubMed ID: 21142586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised trial of the effect of a gastrin/CCK
    Boyce M; van den Berg F; Mitchell T; Darwin K; Warrington S
    Eur J Clin Pharmacol; 2017 Feb; 73(2):129-139. PubMed ID: 27796466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective study of the ability of serial measurements of serum chromogranin A and gastrin to detect changes in tumor burden in patients with gastrinomas.
    Abou-Saif A; Gibril F; Ojeaburu JV; Bashir S; Entsuah LK; Asgharian B; Jensen RT
    Cancer; 2003 Jul; 98(2):249-61. PubMed ID: 12872342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of long-term therapy with proton pump inhibitors on meal stimulated gastrin.
    Helgadóttir H; Metz DC; Yang YX; Rhim AD; Björnsson ES
    Dig Liver Dis; 2014 Feb; 46(2):125-30. PubMed ID: 24210828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastroesophageal reflux disease in primary care: using changes in proton pump inhibitor therapy as an indicator of partial response.
    Ruigómez A; Johansson S; Wernersson B; Fernández Cantero O; García Rodríguez LA
    Scand J Gastroenterol; 2012 Jul; 47(7):751-61. PubMed ID: 22519917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.